Varicella-Zoster Virus gE Escape Mutant VZV-MSP Exhibits an Accelerated Cell-to-Cell Spread Phenotype in both Infected Cell Cultures and SCID-hu Mice  by Santos, Richard A. et al.
s
c
c
w
V
y
M
d
I
Virology 275, 306–317 (2000)
doi:10.1006/viro.2000.0507, available online at http://www.idealibrary.com onVaricella-Zoster Virus gE Escape Mutant VZV-MSP Exhibits an Accelerated Cell-to-Cell Spread
Phenotype in both Infected Cell Cultures and SCID-hu Mice
Richard A. Santos,* Christopher C. Hatfield,* Nancy L. Cole,† Jorge A. Padilla,* Jennifer F. Moffat,‡ Ann M. Arvin,‡
William T. Ruyechan,§ John Hay,§ and Charles Grose*,1
*Department of Microbiology, University of Iowa, Iowa City, Iowa 52242; †Indiana University School of Medicine, SBCME, Notre Dame,
Indiana 46556; ‡Department of Pediatrics, Stanford University School of Medicine, Stanford, California 94305;
and §Department of Microbiology, State University of New York at Buffalo, Buffalo, New York 14214
Received April 10, 2000; returned to author for revision May 10, 2000; accepted July 3, 2000
Varicella-zoster virus is considered to have one of the most stable genomes of all human herpesviruses. In 1998, we
reported the unanticipated discovery of a wild-type virus that had lost an immunodominant B-cell epitope on the gE
ectodomain (VZV-MSP); the gE escape mutant virus exhibited an unusual pattern of egress. Further studies have now
documented a markedly enhanced cell-to-cell spread by the mutant virus in cell culture. This property was investigated by
laser scanning confocal microscopy combined with a software program that allows the measurement of pixel intensity of the
fluorescent signal. For this new application of imaging technology, the VZV immediate early protein 62 (IE 62) was selected
as the fluoresceinated marker. By 48 h postinfection, the number of IE 62-positive pixels in the VZV-MSP-infected culture was
nearly fourfold greater than the number of pixels in a culture infected with a low-passage laboratory strain. Titrations by
infectious center assays supported the above image analysis data. Confirmatory studies in the SCID-hu mouse documented
that VZV-MSP spread more rapidly than other VZV strains in human fetal skin implants. Generally, the cytopathology and
vesicle formation produced by other strains at 21 days postinfection were demonstrable with VZV-MSP at 14 days. To assess
whether additional genes were contributing to the unusual VZV-MSP phenotype, ;20 kb of the VZV-MSP genome was
sequenced, including ORFs 31 (gB), 37 (gH), 47, 60 (gL), 61, 62 (IE 62), 66, 67 (gI), and 68 (gE). Except for a few polymorphisms,
as well as the previously discovered mutation within gE, the nucleotide sequences within most open reading frames were
identical to the prototype VZV-Dumas strain. In short, VZV-MSP represents a novel variant virus with a distinguishable
phenotype demonstrable in both infected cell cultures and SCID-hu mice. © 2000 Academic Press
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1INTRODUCTION
Based on their extensive analyses of herpesviral mo-
lecular evolutionary history, McGeoch and Davison
(1999) estimate that herpesvirus DNA sequences mutate
10–100 times faster than the equivalent classes of se-
quences on the host genome. For glycoprotein gB, a
highly conserved open reading frame (ORF) among all
herpesviruses, they calculate that nonsynonymous sub-
stitutions have occurred at a rate of 2.7 3 1028 substitu-
tions per site per year and synonymous substitutions at
1027 substitutions per site per year (McGeoch and Davi-
on, 1999). McGeoch and Davison (1999) also provide
onvincing arguments in favor of the concept of cospe-
iation; in other words, herpesvirus lineages arise by
ay of coevolution with their specific host. In the case of
ZV, the progenitor virus most likely arose 60–70 million
ears before the present (McGeoch and Cook, 1994;
cGeoch et al., 1995).
1 To whom correspondence and reprint requests should be ad-
ressed at University Hospitals/2501 JCP, 200 Hawkins Drive, Iowa City,aA 52242. Fax: 319-356-4855. E-mail: charles-grose@uiowa.edu.
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306Of all the human herpesviruses, VZV may undergo the
ewest replication cycles during the lifetime of the in-
ected host. Based on a probable schema of pathogen-
sis, the virus actively replicates for a period of 10–14
ays after infection of the human host (Arvin, 1996;
rose, 1999). During a bout of chickenpox, therefore, VZV
as at most 20 replication cycles. Based on our current
nderstanding of VZV latency and reactivation, no further
eplication occurs unless the individual develops herpes
oster in late adulthood. Because of the above scenario,
he genetic stability of the VZV genome has been pre-
umed.
VZV contains the smallest genome of the human her-
esviruses, encoding 69 ORFs within the complete VZV-
umas sequence (Davison and Scott, 1983). Of these
RFs, at least 7 code for glycoproteins (Cohen and
traus, 1996; Grose, 1990; Mo et al., 1999). VZV gE, the
roduct of ORF 68, is the most abundantly produced viral
lycoprotein during infection. Unlike other alphaherpes-
iral homologs, the VZV gE protein is a major antigenic
eterminant, inducing both cytolytic and humoral re-
ponses (Arvin et al., 1986; Bergen et al., 1991; Ito et al.,
985). VZV gE, in complex with glycoprotein I (gI), acts ashuman Fc receptor on the surface of infected cells
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307PHENOTYPE OF MUTANT VZV-MSP(Litwin et al., 1990, 1992). The cytoplasmic tails of both gE
nd gI contain endocytosis motifs, allowing internaliza-
ion and recycling of the complex to and from the cell
embrane (Olson et al., 1997; Olson and Grose, 1997).
The gE and gI cytoplasmic tails also are modified by both
serine/threonine and tyrosine phosphorylation motifs
(Olson et al., 1997; Yao et al., 1993; Ye et al., 1999). The
act that gE cannot be deleted suggests that it is essen-
ial (Cohen and Seidel, 1993; Mallory et al., 1997). Be-
ause of its important functions, the recent discovery of
VZV gE escape mutant (VZV-MSP) was completely
nexpected; based on the prototypic VZV-Dumas se-
uence, the mutant gE protein contains a D150N substi-
ution (Santos et al., 1998). The current report provides a
ore complete characterization of the altered biological
roperties and genetic composition of this contemporary
ariant in VZV evolution. For the first time, we have
iscovered a VZV variant virus which has a cell-to-cell
pread phenotype clearly distinguishable from that of
reviously characterized VZV strains.
RESULTS
ell-to-cell spread phenotype of VZV-MSP
During our initial assessment of VZV-MSP, we ob-
erved that the egress of VZV-MSP particles in cell cul-
ure differed from that of other typical VZV laboratory
trains, such as VZV-32 and VZV-Oka (Santos et al.,
998). Like other VZV strains, however, infectious virus
as not released into the culture medium. The fact that
reater numbers of VZV-MSP particles were present on
he surface suggested that cell-to-cell spread may be
ncreased. Cell-to-cell spread has been assessed in both
SV-1 and PRV through measurement of plaque size in
ermissive cells or the number of cells infected within a
ypical plaque (Dingwell et al., 1994; Tirabassi et al.,
997; Tirabassi and Enquist, 1999). Neither technique is
asily applicable in the VZV system given the formation
f irregularly shaped syncytia by VZV in cell culture and
he absence of cell-free virus in tissue culture. Therefore,
e developed a technique to assess cell-to-cell spread
hrough confocal microscopic examination.
We compared the spread of low-passage VZV-MSP to
hat of the low-passage laboratory strain VZV-32. Human
elanoma cells were inoculated with either VZV-32 or
ZV-MSP at a 1:8 ratio of infected:uninfected cells. At
ncreasing intervals postinfection, the infected monolay-
rs were probed with an antibody against the VZV im-
ediate early protein 62 (IE 62). The number of cells
xpressing IE 62 and the intracellular localization of the
rotein were determined. This assay was based on the
bservation by Kinchington and Turse (1998) that VZV IE
2 is present in the nuclei of infected cells during early
tages of infection, but then appears in the cytoplasm
uring later stages.The confocal micrographs in Figs. 1A and 1B compare
ZV-32 and VZV-MSP at 4 h postinfection. This time point
epresents the number of infected cells originally over-
aid onto each monolayer. Both panels contained similar
evels of IE 62-positive cells. Figures 1C and 1D compare
ZV-32 and VZV-MSP at 24 h postinfection. The differ-
nce in extent of spread between VZV-MSP and VZV-32
as apparent. Figures 1E and 1F represent a typical
ocus of infection present in each monolayer when
iewed at a higher magnification. For VZV-32 in Fig. 1E,
–8 cells with advanced infection were present in each
ocus; IE 62 was present in both nucleus and cytoplasm.
few scattered cells adjacent to the infectious focus
ontained nuclei with IE 62 concentrated near the mem-
rane; these cells represented a recent transfer of infec-
ivity from the central focus. When the VZV-MSP culture
as examined (Fig. 1F), large syncytia had already
ormed at 24 h postinfection. A typical syncytium con-
ained 20–30 nuclei, an infectious focus three- to fourfold
arger than that seen with VZV-32. This experiment was
epeated four times with equivalent results.
uantitative analysis of confocal images of VZV IE 62
To quantify the difference in cell-to-cell spread, multi-
le confocal images were analyzed with the image anal-
sis programs called Brainvox tal_support programs
Frank et al., 1997). Each confocal image is made up of
12 3 512 pixels, for a total of 262,144 pixels. We ana-
lyzed the green fluorescence channel representing the
presence of VZV IE 62 within each confocal image. The
image analysis program initially assigns a relative signal
intensity within each pixel of the confocal image. Then, a
threshold of signal intensity is calculated to remove
background signals. This analysis facilitated quantitation
of all pixels within each confocal image that contained IE
62. Thus, confocal microscopy of IE 62 coupled with
image analysis facilitated a comparison of the extent of
viral spread between two different VZV strains.
The results for this analysis are shown in Fig. 2. Note
that there was no major difference between the extent of
IE 62 spread for VZV-32 and VZV-MSP at 4, 8, and 12 h
postinfection. The results at both 4 and 8 h, in particular,
demonstrated that each monolayer was infected with a
similar inoculum of infected cells. Also, the lack of a
difference between the three time points (4–12 h) con-
firmed that the replication cycle for both VZV strains was
greater than 12 h, in agreement with previous studies
(Yamanishi et al., 1980). However, at 24 h postinfection,
there was a noticeable difference between the spread of
VZV-MSP and VZV-32. The extent of VZV-MSP spread
was at least twofold greater than that of VZV-32. At 48 h
postinfection, this difference increased further, as the
VZV-MSP spread was fourfold greater than that of VZV-
32. Thus, image analysis provided a new method by
which to measure differences in cell-to-cell spread be-
(
s
308 SANTOS ET AL.tween VZV strains. Again, this methodology is particu-
larly suited for VZV because cell-free virus is not re-
FIG. 1. Confocal microscopic imaging of VZV cell-to-cell spread. MeW
B, D, and F) and examined by laser scanning confocal microscopy. T
tained with TOTO-3 appear red. Infected monolayers were examined
320 (E, F).leased spontaneously from infected cell cultures; evenafter sonic disruption of infected monolayers, most viral
particles remain attached to remnants of outer cellular
monolayers were infected with either VZV-32 (A, C, and E) or VZV-MSP
resceinated VZV IE 62 regulatory protein appears green while nuclei
B) and 24 h (C–F) postinfection. Original magnification: 34 (A–D) ando cell
he fluo
at 4 (A,membranes (Grose and Brunell, 1978; Weller, 1953).
309PHENOTYPE OF MUTANT VZV-MSPFIG. 4. Vesicle formation in the VZV-infected SCID-hu mouse model. Skin implants within the SCID-hu mice were harvested on days 7 and 14
postinfection with VZV-MSP; histological analyses were performed as described under Materials and Methods. (A) At day 7, early signs of infection
were visible as small foci in the epidermis. (B) Enlarged view of boxed area in A. The infectious foci were visible in the epidermis (e). The basal lamina
was intact (arrows) and the dermis was uninvolved (d). (C) By day 14, a representative vesicular lesion formed in the epidermis had greatly enlarged.
The basal lamina was disrupted (arrows) and the virus had spread into the dermis. Magnification bars 5 0.5 mm (A, C), 0.05 mm (B).
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310 SANTOS ET AL.VZV infectious center assays
Because the results in the previous experiments rep-
resented a new application of confocal microscopy, we
turned to a traditional method to confirm the differences
in VZV cell-to-cell spread, namely, infectious center as-
says (Cole and Kingsley, 1992; Grose and Brunell, 1978).
For these titrations, the initial virus inocula were replicate
samples of VZV-infected cells frozen and stored in liquid
nitrogen. After being frozen, 1 aliquot was thawed and
titrated from each lot. The inoculum for each 35-mm
tissue culture dish was 500 infectious centers. Two
dishes were harvested and assayed at each of the fol-
lowing time points: immediately after inoculation (0 h)
and 24 and 48 h postinoculation (Fig. 3). When compar-
ing the average fold increase of VZV-MSP infectious
centers to VZV-32 infectious centers, the spread of VZV-
MSP was consistently greater than the spread of VZV-32
over both the first 24-h period (24 h p.i.) and the second
24-h period (48 h p.i.). Otherwise stated, at 48 h postin-
fection, the cytopathic effect of VZV-MSP was complete,
while numerous infectious center titrations with VZV-32
demonstrated that a 60- to 72-h interval was required for
similar spread (Grose and Brunell, 1978). Furthermore,
the rapidity of VZV-32 spread was not altered over the
initial 20 passages. (VZV-Oka and VZV-Ellen titrations
FIG. 2. Quantitative analysis of VZV IE 62 by confocal microscopy.
VZV-MSP- or VZV-32-infected monolayers were examined by confocal
microscopy at increasing times postinfection at 34 original magnifica-
tion. The total number of pixels positive for VZV IE 62 within each image
was quantitated with the Brainvox tal_support programs (University of
Iowa). The graph summarizes the results from four separate images.
Error bars: 61 SD.exhibit a time course similar to that of VZV-32; C. Grose,unpublished observations.) Therefore, results from both
quantitative confocal microscopic image analyses and
infectious center assays documented that the spread of
VZV-MSP was three- to fourfold greater than the spread
of VZV-32.
Growth of VZV-MSP in the SCID-hu mouse
The SCID-hu mouse has provided the first reproduc-
ible animal model of VZV pathogenesis. Published stud-
ies have documented the pathology of viral infection in
human thymus/liver and skin implants after inoculation
with parental and vaccine Oka strains as well as low-
passage wild-type virus (Moffat et al., 1995, 1998a). To
ssess whether VZV-MSP showed enhanced pathology
n the SCID-hu mouse model, skin implants infected with
ZV-MSP were harvested at 7, 14, and 21 days after
nfection. At 7 days postinfection, numerous foci of infec-
ion were visible in the epidermis of the human skin
mplant (Figs. 4A and 4B). By 14 days the foci coalesced
nto large necrotic lesions with histopathology typical of
aricella vesicles (Fig. 4C). These vesicles were charac-
erized by epidermal hyperplasia, balloon cells, and the
eparation of the keratin roof from the epidermis. After 21
ays, the infection had spread into the dermis and de-
troyed the entire implant (Fig. 5A). Samples of the im-
lants also were examined by previously described elec-
FIG. 3. Infectious center assays of VZV-MSP and VZV-32. Infectious
center assays were carried out by previously described methods (Cole
and Kingsley, 1992; Grose and Brunell, 1978). The numbers of infectious
centers present at 24 and 48 h postinfection were determined for
VZV-MSP and VZV-32. The average fold increase of infectious centers
at each interval was tabulated.
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311PHENOTYPE OF MUTANT VZV-MSPtron microscopy methods; the virion formation closely
resembled that shown in Fig. 2 of the report by Moffat et
al. (1998a). Mock-infected skin implants showed normal
skin structure consisting of a thin layer of keratinocytes
above the dermis and hair follicles (Fig. 5B).
Prior published studies had not shown such a rapid
progression of pathology in the SCID-hu mouse infected
with VZV (Moffat et al., 1995, 1998a). To further assess
his aspect of VZV infection in the animal model, another
xperiment was performed with a clinical isolate pas-
aged even fewer times than VZV-32; in addition, the
ow-passage parent VZV-Oka strain was included. Again,
he skin samples were collected and examined at days 7,
4, and 21 postinoculation. When all the specimens were
eviewed, the histopathology of the clinical isolate and
arental VZV-Oka at 21 days postinoculation were simi-
ar, and for both strains the histopathology was ap-
roaching that caused by VZV-MSP at 14 days postin-
FIG. 5. Histological analysis of VZV-MSP infected skin implants at
day 21. (A) VZV-MSP replication extended from the epidermis through-
out the dermis and involved the entire implant, causing loss of normal
skin architecture. Compare with Fig. 4. (B) Normal features of the
epidermis and dermis were observed in the mock-infected control.
Magnification bar 5 0.5 mm.culation (Fig. 6). Even at 21 days, however, the formertwo viral strains never caused the total destruction seen
after VZV-MSP infection (Fig. 5A). In short, the progres-
sion of VZV-MSP through the skin implant was noticeably
more extensive than that seen with other viral strains
tested in the SCID-hu animal model (Figs. 4, 5, and 6).
Genetic analysis of other major glycoproteins
of VZV-MSP
After documenting the enhanced cell-to-cell spread of
VZV-MSP, we questioned whether mutations were
present in ORFs other than gE that may be contributing
to this phenotype. Specifically, we analyzed ORFs 31, 37,
60, and 67 coding for VZV gB, gH, gL, and gI, respectively.
The ORFs were amplified from the VZV-MSP viral ge-
nome and sequenced and then compared to the pub-
lished VZV-Dumas sequence (Davison and Scott, 1986).
Of interest, neither the gI nor the gL gene contained any
nucleotide differences when compared to the nucleotide
FIG. 6. Histological analysis of skin implants infected with parental
VZV-Oka strain at day 21. These images highlight the range of cytopa-
thology induced by parental VZV-Oka at day 21 p.i. (A) Small focus of
infection in the epidermis of the skin implant with no evidence of
penetration of the basal lamina. (B) Vesicle formation with penetration
of the basal lamina and further infectious spread into the dermis.
Compare with Fig. 5. Histopathology for clinical VZV isolate was similar
(data not shown). Magnification bar 5 0.5 mm.
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312 SANTOS ET AL.sequences of VZV-Dumas. Further, the gB sequence was
identical to that of VZV-Dumas. However, VZV-MSP gH
contained a single point mutation within codon 269
(CCA 3 CTA), converting a proline residue in the pre-
dicted VZV-Dumas peptide sequence to a leucine resi-
due in VZV-MSP gH.
Given the presence of mutations within VZV-MSP gE and
gH, we performed similar genetic analyses of VZV-32. As
expected, VZV-32 lacked the D150N mutation within gE.
VZV-32 gH, however, revealed the identical point mutation
found within codon 269 of VZV-MSP gH. Thus, the mutation
within VZV-MSP gH cannot account for the VZV-MSP cell-
spread phenotype. VZV-32 contained one additional muta-
tion within ORF 67 (gI) which would lead to a Q5H substi-
tution (CAA3 CAT). This substitution was within the prob-
able leader sequence of VZV gI and thus would not be
present in mature gI (Davison and Scott, 1986). Altogether,
within five major glycoprotein ORFs, VZV-MSP contained
two point mutations which caused amino acid substitutions
when compared to VZV-Dumas: D150N in gE and P269L in
gH (Fig. 7).
In addition to five ORFs, we sequenced major portions
of the 59 untranslated regions of ORFs 31, 60, 67, and 68.
All regions were identical to VZV-Dumas except for that
of ORF 60. The latter region contained four polymor-
phisms; these ranged from 554 to 1320 nucleotides from
the ORF 60 initiation codon (Fig. 7). It is very unlikely that
FIG. 7. Summary of genetic analysis of VZV-MSP. Each region of DN
ompared to the prototype VZV-Dumas sequence. All mutations discove
ithin open reading frames are followed by the predicted amino acid exthese polymorphisms will alter the expression of gLsince they are located over 500 nucleotides upstream of
the gL start site.
Genetic analysis of VZV-MSP regulatory proteins and
kinases
Although viral glycoproteins are the most likely candi-
dates for mediating the cell-to-cell spread phenotype of
VZV-MSP, we considered the possibility that an alteration
in immediate early regulatory events may contribute to
this enhanced cell-to-cell spread phenotype. VZV ex-
presses one predominant species, IE 62, which acts as
the major regulatory protein for viral gene expression
(Perera et al., 1992, 1993; Piette et al., 1995; Shiraki and
yman, 1987). This protein contains a potent acidic ac-
ivation domain at its N-terminus and is a component of
he virus particle (Kinchington et al., 1992; Perera et al.,
993). Therefore, we sequenced the IE 62 gene of VZV-
SP, but detected only one silent polymorphism within
odon 30 when compared to the Dumas strain (GCG 3
GCC) (Fig. 7). Thus, the peptide sequence of VZV-MSP IE
62 was identical to the predicted VZV-Dumas sequence.
Further, we sequenced the 59 untranslated region con-
taining 525 nucleotides and this region was identical to
that of VZV-Dumas. In addition, we sequenced the adja-
cent VZV-MSP ORF 61, which encodes the functional
homolog of HSV-1 ICP0 (Moriuchi et al., 1992). Again, the
amplified from VZV-MSP and sequenced. Each DNA sequence was
listed by the nucleotide number of the Dumas strain. Any substitutions
by VZV-MSP. Accession numbers are listed in Materials and Methods.A was
red arenucleotide sequence was identical to that of VZV-Dumas.
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313PHENOTYPE OF MUTANT VZV-MSPPrevious studies have shown that the viral protein
kinase VZV ORF 47 can phosphorylate IE 62 (Ng, et al.,
1994). Also, VZV ORF 66 encodes a protein kinase which
has been shown to affect the intracellular localization
and transactivation function of IE 62 (Kinchington and
Turse, 1998; Kinchington et al., 2000). Based upon these
esults, we wanted to determine whether mutations in
hese viral kinases could affect the function of IE 62
ithin VZV-MSP-infected cells. Therefore, we sequenced
oth protein kinase genes within the VZV-MSP genome
nd found both to be identical to the prototype VZV-
umas sequence (Fig. 7). Thus, there was no genetic
vidence of polymorphisms within either of two regula-
ory ORFs or either of two viral protein kinase ORFs. In
hort, after sequence analysis of over 15% of the VZV-
SP genome, the main impression was a striking simi-
arity with VZV-Dumas except for the notable exceptions
entioned earlier.
DISCUSSION
VZV-MSP represents the first reported antigenic vari-
nt of VZV gE or any other virion envelope protein. We
ave previously characterized the effect of the MSP mu-
ation within gE (D150N) on the epitope of the anti-gE 3B3
ntibody (Santos et al., 1998). This amino acid substitu-
ion greatly reduces the affinity of MAb 3B3 to gE, caus-
ng loss of antibody recognition under normal conditions
n both immunofluorescence and Western blot assays.
e observed that this mutation was identical to a known
mino acid substitution caused by antigenic drift in the
nfluenza A hemagglutinin protein and postulated that
ZV-MSP is an escape mutant that circumvents the an-
ibody response following VZV infection (Szomolanyi-
suda and Welsh, 1998; Wharton et al., 1989). We also
ave previously reported that VZV-MSP has a dramati-
ally different topography of viral egress onto the surface
f infected cultured cells compared to VZV-32 and VZV-
ka. The latter two strains normally emerge in a pattern
hich we have designated “viral highways” (Harson and
rose, 1995; also see cover photo of Virology, 249, Sept.
15, 1998). However, VZV-MSP viral particles were more
plentiful and more evenly distributed across the entire
surface of infected cells in a pattern that was similar to
the egress of HSV-1-infected cells (Padilla et al., 1997;
Santos et al., 1998).
Taylor-Robinson and Caunt (1972) detailed the spread
of VZV in cell culture in 1972. They noted that small foci
(“microplaques”) were first detected at 2 days postinfec-
tion; the foci subsequently enlarged over the next 4–8
days. When Cohen and Straus (1996) reviewed the topic
of VZV growth in cultured cells 24 years later, studies
during the intervening decades had revealed relatively
little new information about viral variants. One problem
with assessing differences between strains in VZV
spread and infectivity is the cell-associated nature of VZV tinfection in cultured cells. Numerous investigations over
several decades have discovered that attempts to quan-
titate cell-free virus invariably lead to simultaneous loss
of infectivity, possibly due to loss of the viral envelope.
Thus, most studies are performed with an inoculum of
infected cells rather than cell-free virus.
To circumvent difficulties with virus titration by more
traditional assays, we adapted a software program
called Brainvox tal_support systems to analyze confocal
images of VZV-infected monolayers (Frank et al., 1997). In
confocal microscopic analysis, a laser scans the sample
line by line, generating an excitation signal as it passes
over fluorophores coupled to the secondary antibody.
After this excitation signal enters the photomultiplier
tube, each pixel of the digital image is assigned an
intensity determined by the amount of fluorescence of
that site in the original sample. The range of the gray
scale is from 0 to 255 (8 bit). The software program
calculated for each VZV confocal image the intensity of
the fluorescent signal within each pixel. In general, the
background as determined with uninfected cell controls
had a pixel intensity of less than 25, while positive cells
had a pixel intensity within the 25–255 range. Thereafter,
the Brainvox tal_support programs were instructed to
extract the positive pixels and plot the data as a histo-
gram representing VZV IE-62-positive cells. Through this
quantitative imaging approach, we were able to docu-
ment an accelerated cell-to-cell spread phenotype of
VZV-MSP.
After we had documented two distinct components of
the VZV-MSP phenotype (pattern of viral egress and
enhanced cell-to-cell spread), we postulated that VZV-
MSP would behave differently in the SCID-hu mouse
model. VZV has a highly restricted host range and pre-
vious attempts to study the virus in a variety of experi-
mental animals did not mimic the symptomatic disease
in humans (Arvin, 1996). By implanting human fetal skin
tissue into SCID-hu mice, an animal model was estab-
lished which allowed VZV replication in differentiated
human skin with subsequent formation of vesicular le-
sions, the hallmark of human clinical disease (Moffat et
al., 1995). These studies documented a correlation be-
tween (i) high infectious foci counts, (ii) increased histo-
pathology, and (iii) detectable enveloped virions in the
implants (Moffat et al., 1998a). The morphological fea-
ures of virions from skin implants closely resemble the
omplete enveloped virions seen in samples collected
rom human vesicular fluid; in contrast, samples col-
ected from infected cell cultures rarely show a proto-
ypic enveloped virion but exhibit a spectrum of aberrant
articles (Grose et al., 1995). In the prior study, enveloped
irions were detected in the skin implants 21 days
ostinfection with wild-type virus but not vaccine Oka
irus (Moffat et al., 1998a). The fact that virus was de-
ected in VZV-MSP-infected implants at 14 days postin-
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314 SANTOS ET AL.fection in the current study reinforces the correlation
recognized in the 1998 study.
Previous studies in SCID-hu mice have demonstrated
a reduced virulence of the vaccine strain of VZV-Oka in
comparison to the parental VZV-Oka strain (Moffat et al.,
1998a). The pathogenic properties of laboratory gener-
ated VZV mutants have also been assessed. In one
example, a VZV-ORF 47 deletion mutant replicated effi-
ciently in cultured cells in vitro but could not replicate
ithin differentiated human cells in the SCID-hu model, a
esult which highlighted the importance of this viral ki-
ase in vivo (Moffat et al., 1998b). Thus, the SCID-hu
model has facilitated the characterization of VZV strains
with reduced virulence in differentiated lymphocytes and
skin cells. In juxtaposition, we have now documented for
the first time in the SCID-hu animal model an accelerated
pathogenesis of VZV-MSP over that of other VZV wild-
type isolates and laboratory strains.
The phenotype of the VZV gE mutant virus led us to
reexamine the data about the role of this glycoprotein in
cell-to-cell spread. VZV gE is a 623-amino-acid, type I
transmembrane glycoprotein (Davison and Scott, 1986).
Within the VZV system, gE is considered to be an essen-
tial glycoprotein (Mallory et al., 1997). VZV gE forms a
heterodimer with gI, a 354-amino-acid, type I transmem-
brane glycoprotein whose cytoplasmic tail also contains
both endocytosis and phosphorylation motifs (Olson et
al., 1997; Olson and Grose, 1998; Zhu et al., 1996). The gE
and gI glycoproteins interact via their ectodomains
(Kimura et al., 1997). Not only is VZV gI required for
replication of the virus in Vero cells, but also VZV gI
deletion mutants in melanoma cells show a reduced
cell-to-cell spread phenotype, highlighting the role of this
protein in cell-to-cell spread (Cohen and Nguyen, 1997;
Cohen and Seidel, 1993; Mallory et al., 1997). In addition,
VZV gI acts as a chaperone protein and can facilitate the
efficient endocytosis and subcellular trafficking of gE
lacking its endocytosis motif (Olson and Grose, 1998). Of
interest, gE cannot perform the same function for a
disabled gI protein.
The role of gE in mediating cell-to-cell spread has
been well studied in both HSV-1 and PRV (Dingwell et al.,
1994, 1995; Dingwell and Johnson, 1998; Tirabassi et al.,
1997; Wisner et al., 2000; Zsak et al., 1992). Deletional
mutants of HSV-1 gE and gI exhibit a reduced plaque
size phenotype in tissue culture as well as reduced
neuronal spread in a rat eye model (Dingwell et al., 1994;
Dingwell and Johnson, 1998). Studies in the PRV system
with gE deletional mutants demonstrated a similar re-
duced spread in tissue culture and a rat eye model
(Tirabassi et al., 1997; Zsak et al., 1992). However, HSV-1
E mutants which still expressed the gE ectodomain yet
acked the cytoplasmic domain failed to restore cell-to-
ell spread in tissue culture, but the ectodomain was
ble to mediate localization of gE to tight junctions be-ween cells (Wisner et al., 2000). In contrast, similar PRVgE truncation mutants which still expressed the gE
ectodomain showed partial restoration of cell-to-cell
spread in tissue culture as well as neurotropic spread in
the rat visual system similar to wild-type virus (Tirabassi
et al., 1997). Thus, in studies of alphaherpesviruses other
than VZV, gE plays a crucial role in cell-to-cell spread,
and the gE ectodomain alone can mediate some of these
functions.
We have now sequenced ;20 kb of the VZV-MSP
genome, including the ORFs of five glycoproteins, two
major VZV regulatory proteins, two viral kinases, and
major portions of the 59 untranslated regions of these
ORFs. After evaluating these sequence data, we were
struck by the overall identity of VZV-MSP to the prototype
VZV-Dumas. Although a few polymorphisms were noted,
the majority of these were in untranslated regions (Fig.
7). Other than the previously reported change within
VZV-MSP gE, only one polymorphism (within VZV-MSP
gH) led to a predicted amino acid substitution. Within the
VZV system the gH:gL complex subsumes a prominent
role in fusion (Duus et al., 1995; Rodriguez et al., 1993). In
contrast to HSV-1, monolayers transfected with only the
VZV gH and VZV gL genes are completely fused (Duus et
al., 1995; Duus and Grose, 1996; Turner et al., 1998). Yet,
it appeared unlikely that the one-point mutation at posi-
tion 269 within gH contributed to the VZV-MSP pheno-
type because the same mutation was found in gH of the
laboratory strain VZV-32. In summary, the above data
have strengthened the original observation that the vari-
ant virus has a phenotype clearly distinguishable from
any VZV strain previously studied by the authors of this
article.
MATERIALS AND METHODS
Cells, viruses, and transfer of infectivity
VZV-MSP was isolated in Minnesota in late 1995 (San-
tos et al., 1998). VZV-32 was isolated in Texas in the
1970s (Grose and Brunell, 1978). Reserve stocks of
VZV-32 and VZV-MSP were prepared; thus low passages
(,20) were used in all experiments in this report. VZV-
Oka was isolated in Japan and attenuated in the 1970s
(Takahashi et al., 1975). VZV-Dumas was isolated in Hol-
land and sequenced in its entirety by Davison and Scott
(1986). All strains were propagated in human melanoma
cells (MeWo strain). MeWo cells are highly permissive for
VZV replication with no release of infectious virus into the
culture medium (Grose, 1980). Transfer of infectivity was
carried out by inoculation of trypsin-dispersed infected
cells onto an uninfected monolayer at a 1:8 ratio of
infected:uninfected cells unless otherwise noted (Grose
and Brunell, 1978). Similarly, infectious center assays
were carried out by described methods; these assays
included both melanoma cell and human neonatal fore-
skin cell substrates (Cole and Kingsley, 1992; Grose and
Brunell, 1978).
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315PHENOTYPE OF MUTANT VZV-MSPImaging by confocal microscopy
Replicate 35-mm monolayers of MeWo cells were
overlaid with VZV-infected cells at a 1:8 ratio of infected:
uninfected cells. At 4, 8, 12, 24, and 48 h postinfection,
the monolayers were fixed and permeabilized with 0.5 ml
of 2% paraformaldehyde with 0.05% Triton X-100. Cells
were probed with an anti-IE-62 mouse monoclonal as-
cites (MAb 5C6) at a dilution of 1:1000 (Ng et al., 1994).
he secondary antibody was goat anti-mouse IgG F(ab9)2
conjugated to Alexa 488 at a dilution of 1:2500 (Molecu-
lar Probes). Cell nuclei were stained with TOTO-3 (Mo-
lecular Probes), a dimeric cyanine nucleic acid stain, at
a dilution of 1:10,000. Samples were examined with a
Bio-Rad 1024 laser scanning confocal microscope, as
described (Duus et al., 1995).
Quantitative analysis of confocal images
Confocal images were converted to TIFF format im-
ages (Confocal Assistant, v. 4.02) and transferred to a
Silicon Graphics Indy workstation in order to produce the
color prints by Showcase software program. Confocal
images also were analyzed with the Brainvox tal_support
programs (Frank et al., 1997). Similar analyses can be
performed with the public domain NIH Image program,
which was developed at the U.S. National Institutes of
Health (http://rsb.info.nih.gov/nih-image/).
Replication in the SCID-hu mouse
The SCID-hu mouse has been established as an ani-
mal model for VZV replication (Moffat et al., 1995). In this
model, C.B-17 scid/scid mice were implanted with fetal
skin tissue subcutaneously as full-thickness dermal
grafts. Human fetal tissues were obtained with informed
consent according to federal and state regulations and
were screened for human immunodeficiency virus. The
general care of the experimental animals used for this
study was in accordance with the National Institutes of
Health guidelines for laboratory animals and in compli-
ance with the Animal Welfare Act (Public Law 94-279) as
well as the Stanford University Administrative Panel on
Laboratory Animal Care. Animal inoculations were per-
formed according to the previously described protocol
(Moffat et al., 1995), viz., an aliquot of infected cell sus-
pension containing 105 infectious centers was injected
nto each implant. Mock-infected implants were injected
ith human cells alone. Skin implants were harvested at
, 14, and 21 days postinoculation. The implants were
ixed in 4% paraformaldehyde, paraffin-embedded, cut
nto 3-mm sections, and stained with hematoxylin and
eosin. Tissue sections were examined on a Leitz Diaplan
light microscope, and digital images were acquired with
an Optronics DEI 750 digital camera (Optronics Engi-
neering). Digital images were formatted as described
above.Isolation of viral DNA
For all viral strains, a 25-cm2 monolayer of MeWo cells
was infected as described above. After development of
80–100% cytopathology, the infected monolayer was
washed thrice with 0.5 ml of 0.01 M phosphate-buffered
saline (PBS), pH 7.4. Infected cells were then harvested
by dislodging into 0.5 ml of PBS. Viral DNA was collected
with a DNAeasy kit following the Blood and Body Fluid
Protocol (Qiagen, Inc.). Following the DNAeasy protocol,
DNA was placed onto a Microcon 50 filter (Millipore) and
washed twice with 0.5 ml of Nanopure water (Barnstead/
Thermolyne). Viral DNA was resuspended in 100 mL of
anopure water. DNA concentration was assessed visu-
lly after 1% agarose gel electrophoresis.
CR amplification and sequencing of VZV genes
For each ORF, a pair of flanking primers was designed
o amplify the gene of interest. PCR amplifications were
erformed with the Expand High-Fidelity PCR system
Boehringer Mannheim). This system utilizes both Taq
NA and Pwo DNA polymerases, with the 39–59 proof-
reading activity of Pwo DNA polymerase allowing in-
creased fidelity (8.5 3 1026/bp error rate) (Boehringer
annheim). After amplification, the PCR product was
equenced by using the dye terminator cycle sequencing
hemistry with AmpliTaq DNA polymerase, FS enzyme
Perkin–Elmer Applied Biosystems, Foster City, CA). Se-
uencing reactions were performed on and analyzed
ith an Applied Biosystems Model 373A stretch fluores-
ent automated sequencer (Perkin–Elmer) at the Univer-
ity of Iowa DNA facility. All genes were PCR amplified
wice and each PCR fragment was sequenced at least
wice to confirm reported mutations. The accession num-
er for the complete VZV-Dumas sequence is X04370.
enBank deposition
The genomic sequences of VZV-MSP described in the
esults were submitted to GenBank, Bethesda, Mary-
and. The accession numbers for the six viral DNA seg-
ents are AY005330, AY005331, AY005332, AY005333,
Y005334 and AY005335.
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